Risk of androgen deprivation therapy after active surveillance for prostate cancer: A real-world analysis
- 18 September 2026
- journal article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (11) , 866-872
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Modifiable Cardiovascular Risk Factors Amongst Men With and Without Prostate Cancer in a Large, Prospective RegistryClinical Genitourinary Cancer, 2025
- Trends in Active Surveillance for Men With Intermediate-Risk Prostate CancerJAMA Network Open, 2024
- Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the USJAMA Network Open, 2023
- Advanced age portends poorer prognosis after radical prostatectomy: a single center experienceAging Clinical and Experimental Research, 2022
- Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor InhibitorsClinical Genitourinary Cancer, 2021
- What matters to people aged 80 and over regarding ambulatory care? A systematic review and meta-synthesis of qualitative studiesEuropean Journal of Ageing, 2021
- Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade DiseaseEuropean Urology Focus, 2021
- Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysisEuropean Urology, 2015
- Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate ThemEuropean Urology, 2015
- Androgen-Deprivation Therapy and the Risk of Stroke in Patients With Prostate CancerEuropean Urology, 2011